BiotechTube
Home/Xeris Pharmaceuticals/Barry M. Deutsch
BM

Barry M. Deutsch

Chief Financial Officer

Xeris Pharmaceuticals

Therapeutic Areas

EndocrinologyRare DiseasesNeurologyMetabolic Disorders

Xeris Pharmaceuticals Pipeline

DrugIndicationPhase
Gvoke (glucagon)Severe HypoglycemiaApproved
Gvoke PFSPediatric Severe HypoglycemiaApproved
Keveyis (dichlorphenamide)Primary Periodic ParalysisApproved
Recorlev (levoketoconazole)Endogenous Cushing's SyndromeApproved
XP-8121 (Liquid Glucagon)Bi-hormonal Pump for DiabetesPhase 2
XP-8121Congenital HyperinsulinismPreclinical/Phase 1
OgluoSevere HypoglycemiaApproved

Leadership Team at Xeris Pharmaceuticals

PR
Paul R. Edick
Chairman and Chief Executive Officer
JP
John P. Schmid
Chief Business Officer
KE
Kenneth E. Johnson
Chief Scientific Officer
SP
Steven Prestrelski
Chief Technology Officer and Co-Founder
RD
R. Drew Nordlicht
Chief Commercial Officer
BP
Beth P. Hecht
Chief Legal Officer and Corporate Secretary
BJ
Brett J. Zbar
Chief Operating Officer
TW
Timothy Walbert
Director
DS
Darren S. Cline
Director
GA
Garry A. Neil
Director
View full Xeris Pharmaceuticals profile